Comment on the article “Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology”

Detalles Bibliográficos
Autor principal: Żuber, Zbigniew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2018
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330681/
https://www.ncbi.nlm.nih.gov/pubmed/30647490
http://dx.doi.org/10.5114/reum.2018.80726
_version_ 1783387012046258176
author Żuber, Zbigniew
author_facet Żuber, Zbigniew
author_sort Żuber, Zbigniew
collection PubMed
description
format Online
Article
Text
id pubmed-6330681
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
record_format MEDLINE/PubMed
spelling pubmed-63306812019-01-15 Comment on the article “Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology” Żuber, Zbigniew Reumatologia Letter to the Editor Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2018-12-23 2018 /pmc/articles/PMC6330681/ /pubmed/30647490 http://dx.doi.org/10.5114/reum.2018.80726 Text en Copyright: © 2018 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Letter to the Editor
Żuber, Zbigniew
Comment on the article “Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology”
title Comment on the article “Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology”
title_full Comment on the article “Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology”
title_fullStr Comment on the article “Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology”
title_full_unstemmed Comment on the article “Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology”
title_short Comment on the article “Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology”
title_sort comment on the article “tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the polish society for rheumatology”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330681/
https://www.ncbi.nlm.nih.gov/pubmed/30647490
http://dx.doi.org/10.5114/reum.2018.80726
work_keys_str_mv AT zuberzbigniew commentonthearticletofacitinibinthetreatmentofpatientswithrheumatoidarthritispositionstatementofexpertsofthepolishsocietyforrheumatology

Ejemplares similares